Adding immunotherapy to chemoradiation therapy (CRT) for limited-stage small cell lung cancer (SCLC) failed to improve ...

A third large trial has shown that hypofractionated, whole-breast irradiation with simultaneous integrated boost is effective ...

Wednesday announced a clinical trial collaboration agreement with AstraZeneca (AZN) to evaluate casdatifan in combination with volrustomig for the treatment of clear cell renal cell carcinoma or ccRCC ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced ...

Owkin has partnered with AstraZeneca to develop an AI gBRCA pre-screen solution for breast cancer. Takeaway Points Owkin has ...

Bank of America Securities analyst Sachin Jain has reiterated their bullish stance on AZN stock, giving a Buy rating on September 30. Sachin ...

The Israeli-American unicorn company ImmunAI has signed a multi-year cooperation agreement with the pharmaceutical giant ...

Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and ...

Big Pharma is investing heavily in AI to slash development timelines and foster innovation. | Big Pharma is investing heavily ...

AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has ...

The solution will use Owkin's data network and artificial intelligence to pre-screen for gBRCA mutations in breast cancer directly from digital pathology slides.

Ever wondered what one of the world’s top oncology leaders believe to be the next big thing in cancer care? Find out in our interview AstraZeneca's Dr Sunil Verma.